Related references
Note: Only part of the references are listed.Neutrophils in multiple sclerosis are characterized by a primed phenotype
Matthias Naegele et al.
JOURNAL OF NEUROIMMUNOLOGY (2012)
Memory Type 2 Helper T Cells Induce Long-Lasting Antitumor Immunity by Activating Natural Killer Cells
Masayuki Kitajima et al.
CANCER RESEARCH (2011)
Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis
J. E. Martinez-Rodriguez et al.
CLINICAL IMMUNOLOGY (2011)
Analyses of phenotypic and functional characteristics of CX3CR1-expressing natural killer cells
Isabell Hamann et al.
IMMUNOLOGY (2011)
Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study
E. Le Page et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Mitoxantrone treatment in multiple sclerosis induces TH2-type cytokines
A. Vogelgesang et al.
ACTA NEUROLOGICA SCANDINAVICA (2010)
CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells
Kerstin Juelke et al.
BLOOD (2010)
Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education
Niklas K. Bjorkstrom et al.
BLOOD (2010)
Extensive infiltration of neutrophils in the acute phase of experimental autoimmune encephalomyelitis in C57BL/6 mice
Fenglan Wu et al.
HISTOCHEMISTRY AND CELL BIOLOGY (2010)
Mitoxantrone and cytotoxic drugs' mechanisms of action
Timothy Vollmer et al.
NEUROLOGY (2010)
Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate
K. L. Sand et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2009)
Initiation and Progression of Axonopathy in Experimental Autoimmune Encephalomyelitis
Athena M. Soulika et al.
JOURNAL OF NEUROSCIENCE (2009)
Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required
Ana M. Pascual et al.
MULTIPLE SCLEROSIS JOURNAL (2009)
SEVERE CARDIAC FAILURE IN A PATIENT WITH MULTIPLE SCLEROSIS FOLLOWING LOW-DOSE MITOXANTRONE TREATMENT
J. Doerr et al.
NEUROLOGY (2009)
Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells
Philip L. De Jager et al.
BRAIN (2008)
CD27 defines phenotypically and functionally different human NK cell subsets
Mireille T. M. Vossen et al.
JOURNAL OF IMMUNOLOGY (2008)
New developments in understanding and treating neuroinflammation
C. Infante-Duarte et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2008)
Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis
F. Paul et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2007)
Neuronal damage in brain inflammation
Orhan Aktas et al.
ARCHIVES OF NEUROLOGY (2007)
Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis
B Bielekova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
In vivo effects of mitoxantrone on the production of pro- and anti-inflammatory cytokines by peripheral blood mononuclear cells of secondary progressive multiple sclerosis patients
Francesco Angelucci et al.
NEUROIMMUNOMODULATION (2006)
Multiple sclerosis:: Mitoxantrone promotes differential effects on immunocompetent cells in vitro
O Neuhaus et al.
JOURNAL OF NEUROIMMUNOLOGY (2005)
Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients
A Chan et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2005)
Profiling the CD8low phenotype, an alternative career choice for CD8 T cells during primary differentiation
N Kienzle et al.
IMMUNOLOGY AND CELL BIOLOGY (2004)
The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
DS Goodin et al.
NEUROLOGY (2003)
Human CD8 T cells of the peripheral blood contain a low CD8 expressing cytotoxic/effector subpopulation
A Trautmann et al.
IMMUNOLOGY (2003)
Rapid onset Mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis
JR Avasarala et al.
MULTIPLE SCLEROSIS (2003)
Effects of mitoxantrone on multiple sclerosis patients' lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10
J Gbadamosi et al.
EUROPEAN NEUROLOGY (2003)
Mitoxantrone in progressive multiple sclerosis:: a placebo-controlled, double-blind, randomised, multicentre trial
HP Hartung et al.
LANCET (2002)
Share Paper
